Publications for Leslie Citrome nntman@gmail.com
Citrome, L. (2014). Physician heal thyself: adventures in hypertension. International Journal of Clinical Practice, 68(11), 1283. doi:10.1111/ijcp.12571
Citrome, L. (2014). Quantifying clinical relevance. Innovations in Clinical Neuroscience, 11(5-6), 26-30.
Citrome, L. (2014). Suvorexant for insomnia: A systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice, 68(12), 1429-1441. doi:10.1111/ijcp.12568
Citrome, L. (2014). The Sunshine Act and transfers of value: Impact on non-industry authorship. Innovations in Clinical Neuroscience, 11(3-4), 14-16.
Citrome, L. (2014). Treatment of bipolar depression: Making sensible decisions. CNS Spectrums, 19(Supp.S1), 1-12. doi:10.1017/S109285291400056X
Citrome, L. (2014). Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. The Journal of Clinical Psychiatry, 75(Suppl 1), 21-26. doi:10.4088/JCP.13049su1c.04
Citrome, L. (2014). Vortioxetine for major depressive disorder: A systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice, 68(1), 60-82. doi:10.1111/ijcp.12350
Citrome, L., & Magnusson, K. (2014). Paging Dr Cohen, Paging Dr Cohen... An effect size interpretation is required STAT!: visualising effect size and an interview with Kristoffer Magnusson. International Journal of Clinical Practice, 68(5), 533-534. doi:10.1111/ijcp.12435
Citrome, L., & Volavka, J. (2014). The psychopharmacology of violence: Making sensible decisions. CNS Spectrums, 19(5), 411-8. doi:10.1017/S1092852914000054
Citrome, L., Johnston, S., Nadkarni, A., Sheehan, J. J., Kamat, S. A., & Kalsekar, I. (2014). Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and medicaid insured patients newly initiating atypical antipsychotics. Current Drug Safety, 9(3), 227-235. doi:10.2174/1574886309666140601211551
Citrome, L., Kalsekar, I., Baker, R. A., & Hebden, T. (2014). A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Current Medical Research and Opinion, 30(8), 1629-1641. doi:10.1185/03007995.2014.908280
Citrome, L., Kamat, S. A., Sapin, C., Baker, R. A., Eramo, A., Ortendahl, J., . . . Gutierrez, B. (2014). Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of Medical Economics, 17(8), 567-576. doi:10.3111/13696998.2014.917089
Citrome, L., Karagianis, J., Maguire, G. A., & Nierenberg, A. A. (2014). Pharmaism: a tale of two perspectives refers to Int J Clin Pract. 2014 Jun;68(6):662-5. PMID: 24837088; International Journal of Clinical Practice, 68(6), 659-661. doi:10.1111/ijcp.12460
Citrome, L., Ketter, T. A., Cucchiaro, J., & Loebel, A. (2014). Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 155, 20-27. doi:10.1016/j.jad.2013.10.040
Citrome, L., Weiden, P. J., McEvoy, J. P., Correll, C. U., Cucchiaro, J., Hsu, J., & Loebel, A. (2014). Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: A 6-month, open-label, extension study. CNS Spectrums, 19(4), 330-339. doi:10.1017/S109285291300093X
Ketter, T. A., Miller, S., Dell'Osso, B., Calabrese, J. R., Frye, M. A., & Citrome, L. (2014). Balancing benefits and harms of treatments for acute bipolar depression. Journal of Affective Disorders, 169(Suppl 1), S24-S33. doi:S0165-0327(14)70006-0
Markowitz, M. A., Levitan, B. S., Mohamed, A. F., Johnson, F. R., Bridges, J. F., Alphs, L., & Citrome, L. (2014). Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment. Psychiatric Services (Washington, D.C.), 65(9), 1133-1139. doi:10.1176/appi.ps.201300290
Pratts, M., Citrome, L., Grant, W., Leso, L., & Opler, L. A. (2014). A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatrica Scandinavica, 130(1), 61-68. doi:10.1111/acps.12262
Volavka, J., Czobor, P., Citrome, L. & Van Dorn, R. A. (2014). Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectrums, 19(5), 374-381. doi:10.1017/S1092852913000849
Weiden, P. J., Citrome, L., Alva, G., Brams, M., Glick, I. D., Jackson, R., . . . Winseck, A. (2014). A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophrenia Research, 153(1-3), 160-168. doi:10.1016/j.schres.2013.11.042
Citrome, L. (2013). A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: An evidence-based medicine approach. CNS Drugs, 27(11), 879-911. doi:10.1007/s40263-013-0105-7
Citrome, L. (2013). Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: Focus on inhaled loxapine as an alternative to injectable agents. Therapeutics and Clinical Risk Management, 9, 235-245. doi:10.2147/TCRM.S31484
Citrome, L. (2013). Cariprazine: Chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opinion on Drug Metabolism and Toxicology, 9(2), 193-206. doi:10.1517/17425255.2013.759211
Citrome, L. (2013). Cariprazine in bipolar disorder: Clinical efficacy, tolerability, and place in therapy. Advances in Therapy, 30(2), 102-113. doi:10.1007/s12325-013-0004-9
Citrome, L. (2013). Cariprazine in schizophrenia: Clinical efficacy, tolerability, and place in therapy. Advances in Therapy, 30(2), 114-126. doi:10.1007/s12325-013-0006-7
